|
|
 |
|
Viewing report
|
|
|
|
Emerging Cancer Diagnostic Tests and Companies Developing New Technologies
Venture Planning Group, Dec 2011, Pages: 260
The report provides a comprehensive marketing and technological assessment, as well as medical rationale and diagnostic prospects, for the major categories of both circulating and cellular tests, such as Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains and others.
The report presents an overview of the clinical significance and market needs for both current and emerging cancer diagnostic tests, as well as extensive listings of companies, universities and research centers developing or marketing new technologies, products, and applications.
Key topics covered:
- Tumor Marker Classification
- ACTH
- Alpha-Fetoprotein (AFP)
- Beta-2 Microglobulin
- CA 15-3/27.29
- CA 19-9
- CA-125
- Calcitonin
- Carcinoembrionic Antigen (CEA)
- Estrogen and Progesterone Receptors
- Ferritin
- Gastrin
- Human Chorionic Gonadotropin (HCG)
- Insulin
- Lymphocytes CD4/CD8
- NSE
- Occult Blood
- PAP Smear/HPV
- Prostatic Acid Phosphatase (PAP)
- Prostate-Specific Antigen (PSA)
- Squamous Cell Carcinoma Antigen (SCC)
- TdT
- Thyroglobulin
- Tissue Polypeptide Antigen (TPA)
- Biochemical Tumor Markers
- Oncogenes
- Ectopic Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains
- Emerging Tumor Markers
Contains 260 pages and 30 tables
|
|
|
|
